Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-5 of 5 (Search time: 0.003 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLarson, R.; Hochhaus, A.; Hughes, T.; Clark, R.; Etienne, G.; Kim, D.; Flinn, I.; Kurokawa, M.; Moiraghi, B.; Yu, R.; Blakesley, R.; Gallagher, N.; Saglio, G.; Kantarjian, H.
2012Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibWhite, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.
2012Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaYin, O.; Giles, F.; Baccarani, M.; le Coutre, P.; Chiparus, O.; Gallagher, N.; Saglio, G.; Hughes, T.; Hochhaus, A.; Kantarjian, H.; Larson, R.
2012Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phaseLarson, R.; Yin, O.; Hochhaus, A.; Saglio, G.; Clark, R.; Nakamae, H.; Gallagher, N.; Demirhan, E.; Hughes, T.; Kantarjian, H.; le Coutre, P.
2012Suboptimal responses in chronic myeloid leukemia: implications and management strategiesJabbour, E.; Saglio, G.; Hughes, T.; Kantarjian, H.